October 18, 2021

Medical Trend

Medical News and Medical Resources

COVID-19: New drug Apidin 27.5 times better than Remdesivir

COVID-19: New drug Apidin 27.5 times better than Remdesivir

 

COVID-19: New drug Apidin 27.5 times better than Remdesivir.  The new drug Apidin is 27.5 times stronger than remdesivir in the treatment of new coronavirus pneumonia.

COVID-19: New drug Apidin 27.5 times better than Remdesivir

The global COVID-19 epidemic is severe, and medical researchers are constantly looking for ways to treat it.

According to data from the World Health Organization, the cumulative number of confirmed cases of COVID-19 in the world has exceeded 100 million, and the epidemic is still spreading globally. Although a number of COVID-19 vaccines have been approved for marketing, there is still a lack of specific drugs.

Recently, a large international research team composed of medical research institutions in the United States, France, and the West brought surprises: In a laboratory environment, the efficacy of the potential new drug Plitidepsin for new coronavirus pneumonia beats Remdesivir. The research was published in the journal Science.

 

With the spread of the COVID-19 epidemic, medical researchers have been looking for drugs approved by regulatory agencies such as the FDA to treat them-“old drugs and new applications” are much faster than new drug development, testing and testing. Remdesivir is therefore used to treat patients with new coronavirus pneumonia.

According to good doctors, Radixivir can inhibit RNA-dependent RNA synthetase (RdRp). It was first designed to fight Ebola virus and was proven to be effective against a variety of coronaviruses in animal models. In the early stages of the epidemic, the efficacy of Redecive in some cases has brought confidence to patients and medical staff worldwide. Chinese netizens gave it the nickname “People’s Hope” based on its pronunciation. The drug has been urgently approved by the FDA to treat new coronavirus pneumonia.

However, the overall curative effect of Redcivir is not satisfactory. For many patients, its curative effect is not satisfactory and cannot be regarded as a “specific drug”.

Countless people around the world are still infected or even dying from new coronavirus pneumonia. Researchers are trying to shift the focus from drugs such as remdesivir to some new directions: remdesivir suppresses the virus by attacking the protein on the surface of the new coronavirus; and in new research Researchers hope to find a drug that works by inhibiting the production of human proteins, which are necessary for the survival of the virus.

 

The effort paid off. The researchers found a drug called Plitidepsin (Aplidin), which has been approved in Australia for the treatment of multiple myeloma (MM). This drug is derived from the Mediterranean sea squirt and can specifically bind to eEF1A (a protein used by cells to produce other proteins) to inhibit the production of eEF1A, thereby triggering tumor cell apoptosis. Previous studies have shown that the new coronavirus requires eEF1A to produce its protein. Without this protein, the virus would die.

In the laboratory, researchers used lung tissue models infected with the new coronavirus to test the efficacy of the drug. The results show that it is 27.5 times as effective as remdesivir in killing the new coronavirus. The research team also tested the effectiveness of the drug in a mouse model infected with the new coronavirus, and found that it greatly reduced the viral load and effectively inhibited virus replication.

 

The researchers pointed out:

The advantage of using drugs that target human proteins rather than viral proteins is that such drugs are unlikely to make viruses resistant to them. Next, the research team will conduct clinical trials to further study the safety and effectiveness of Plitidepsin for patients with new coronavirus pneumonia

 

(source:internet, reference only)


Disclaimer of medicaltrend.org